Literature DB >> 30244333

Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans.

Shahar Azar1, Shiri Sherf-Dagan2,3,4, Alina Nemirovski1, Muriel Webb2, Asnat Raziel5, Andrei Keidar6, David Goitein4,5,7, Nasser Sakran5,8,9, Oren Shibolet2,4, Joseph Tam10, Shira Zelber-Sagi11,12.   

Abstract

BACKGROUND: The endocannabinoid (eCB) system plays a key role in the development of obesity and its comorbidities. Limited information exists on the changes in circulating eCBs following bariatric surgery.
OBJECTIVES: This study aims to (i) assess the circulating levels of eCBs and related molecules and (ii) examine the association between their levels and numerous clinical/metabolic features pre- and post-operatively.
METHODS: Sixty-five morbidly obese patients (age 42.78 ± 9.27 years; BMI 42.00 ± 5.01 kg/m2) underwent laparoscopic sleeve gastrectomy (LSG) surgery, and were followed up for 12 months. Data collected included anthropometrics and metabolic parameters. The serum levels of the eCBs, 2-arachidonoylglycerol (2-AG), anandamide (AEA); and their related molecules, arachidonic acid (AA) and oleoylethanolamine (OEA) were measured by liquid chromatography-mass spectrometry.
RESULTS: Levels of 2-AG, AEA, and AA were reduced post operatively with no differences in serum OEA levels. The delta changes in eCB levels between pre- and post-operation were correlated with the delta of different metabolic parameters. Positive correlations were found between delta AA and waist circumference (WC) (r = 0.28, P < 0.05), free fat mass (r = 0.26, P < 0.05), SteatoTest score (r = 0.45, P < 0.05), and ALT (r = 0.32, P < 0.05). Delta AEA levels positively correlated with WC (r = 0.30, P < 0.05). Delta 2-AG levels positively correlated with total cholesterol (r = 0.27, P < 0.05), triglycerides (r = 0.55, P < 0.05), and SteatoTest score (r = 0.27, P < 0.05). Delta OEA levels negatively correlated with fasting glucose levels (r = - 0.27, P < 0.05).
CONCLUSIONS: This study provides compelling evidence that LSG surgery induces reductions in the circulating 2-AG, AEA, and AA levels, and that these changes are associated with clinical benefits related to the surgery including reduced fat mass, hepatic steatosis, glucose, and improved lipid profile.

Entities:  

Keywords:  Endocannabinoids; Laparoscopic sleeve gastrectomy; Metabolic parameters; Obesity

Mesh:

Substances:

Year:  2019        PMID: 30244333     DOI: 10.1007/s11695-018-3517-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  31 in total

1.  CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance.

Authors:  Carmelo Quarta; Luigi Bellocchio; Giacomo Mancini; Roberta Mazza; Cristina Cervino; Luzie J Braulke; Csaba Fekete; Rocco Latorre; Cristina Nanni; Marco Bucci; Laura E Clemens; Gerhard Heldmaier; Masahiko Watanabe; Thierry Leste-Lassere; Marlène Maitre; Laura Tedesco; Flaminia Fanelli; Stefan Reuss; Susanne Klaus; Raj Kamal Srivastava; Krisztina Monory; Alessandra Valerio; Annamaria Grandis; Roberto De Giorgio; Renato Pasquali; Enzo Nisoli; Daniela Cota; Beat Lutz; Giovanni Marsicano; Uberto Pagotto
Journal:  Cell Metab       Date:  2010-04-07       Impact factor: 27.287

Review 2.  Bariatric endoscopy: state-of-the-art.

Authors:  Vivek Kumbhari; Christine Hill; Shelby Sullivan
Journal:  Curr Opin Gastroenterol       Date:  2017-09       Impact factor: 3.287

3.  Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease.

Authors:  Shira Zelber-Sagi; Shahar Azar; Alina Nemirovski; Muriel Webb; Zamir Halpern; Oren Shibolet; Joseph Tam
Journal:  Obesity (Silver Spring)       Date:  2016-11-15       Impact factor: 5.002

4.  Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease.

Authors:  Jukka Westerbacka; Anna Kotronen; Barbara A Fielding; John Wahren; Leanne Hodson; Julia Perttilä; Tuulikki Seppänen-Laakso; Tapani Suortti; Johanna Arola; Rolf Hultcrantz; Sandra Castillo; Vesa M Olkkonen; Keith N Frayn; Matej Orešič; Hannele Yki-Järvinen
Journal:  Gastroenterology       Date:  2010-06-27       Impact factor: 22.682

5.  Gastric bypass in morbid obese patients is associated with reduction in adipose tissue inflammation via N-oleoylethanolamide (OEA)-mediated pathways.

Authors:  Fabrizio Montecucco; Sébastien Lenglet; Alessandra Quercioli; Fabienne Burger; Aurélien Thomas; Estelle Lauer; Analina Raquel da Silva; François Mach; Nicolas Vuilleumier; Elisabetta Bobbioni-Harsch; Alain Golay; Thomas H Schindler; Zoltan Pataky
Journal:  Thromb Haemost       Date:  2014-11-20       Impact factor: 5.249

6.  Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study.

Authors:  Joseph Abdulnour; Siham Yasari; Rémi Rabasa-Lhoret; May Faraj; Stefania Petrosino; Fabiana Piscitelli; Denis Prud' Homme; Vincenzo Di Marzo
Journal:  Obesity (Silver Spring)       Date:  2013-10-19       Impact factor: 5.002

7.  Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.

Authors:  Douglas Osei-Hyiaman; Jie Liu; Liang Zhou; Grzegorz Godlewski; Judith Harvey-White; Won-il Jeong; Sándor Bátkai; Giovanni Marsicano; Beat Lutz; Christoph Buettner; George Kunos
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

8.  Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors.

Authors:  V Di Marzo; M Côté; I Matias; I Lemieux; B J Arsenault; A Cartier; F Piscitelli; S Petrosino; N Alméras; J-P Després
Journal:  Diabetologia       Date:  2009-02       Impact factor: 10.122

9.  Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis.

Authors:  Akhila Mallipedhi; Sarah L Prior; Gareth Dunseath; Richard M Bracken; Jonathan Barry; Scott Caplin; Nia Eyre; James Morgan; John N Baxter; Saoirse E O'Sullivan; Sarir Sarmad; David A Barrett; Stephen C Bain; Steve D Luzio; Jeffrey W Stephens
Journal:  J Diabetes Res       Date:  2015-03-22       Impact factor: 4.011

10.  Endocannabinoids measurement in human saliva as potential biomarker of obesity.

Authors:  Isabelle Matias; Blandine Gatta-Cherifi; Antoine Tabarin; Samantha Clark; Thierry Leste-Lasserre; Giovanni Marsicano; Pier Vincenzo Piazza; Daniela Cota
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more
  12 in total

Review 1.  Metabolomics in Bariatric Surgery: Towards Identification of Mechanisms and Biomarkers of Metabolic Outcomes.

Authors:  Jane Ha; Yeongkeun Kwon; Sungsoo Park
Journal:  Obes Surg       Date:  2021-07-27       Impact factor: 4.129

Review 2.  Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome.

Authors:  Shira Hirsch; Joseph Tam
Journal:  Toxins (Basel)       Date:  2019-05-15       Impact factor: 4.546

3.  Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption.

Authors:  Shelly Tartakover Matalon; Shahar Azar; David Meiri; Rivka Hadar; Alina Nemirovski; Narjes Abu Jabal; Fred Meir Konikoff; Liat Drucker; Joseph Tam; Timna Naftali
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-31       Impact factor: 5.555

Review 4.  Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism.

Authors:  Volatiana Rakotoarivelo; Jyoti Sihag; Nicolas Flamand
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

5.  Role of Endocannabinoids in Energy-Balance Regulation in Participants in the Postobese State-a PREVIEW Study.

Authors:  Mathijs Drummen; Lea Tischmann; Blandine Gatta-Cherifi; Daniela Cota; Isabelle Matias; Anne Raben; Tanja Adam; Margriet Westerterp-Plantenga
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

Review 6.  Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol.

Authors:  Patrycja Bielawiec; Ewa Harasim-Symbor; Adrian Chabowski
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-04       Impact factor: 5.555

Review 7.  Sample Preparation Methods for Lipidomics Approaches Used in Studies of Obesity.

Authors:  Ivan Liakh; Tomasz Sledzinski; Lukasz Kaska; Paulina Mozolewska; Adriana Mika
Journal:  Molecules       Date:  2020-11-13       Impact factor: 4.411

8.  Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.

Authors:  Shahar Azar; Shiran Udi; Adi Drori; Rivka Hadar; Alina Nemirovski; Kiran V Vemuri; Maya Miller; Dana Sherill-Rofe; Yhara Arad; Devorah Gur-Wahnon; Xiaoling Li; Alexandros Makriyannis; Danny Ben-Zvi; Yuval Tabach; Iddo Z Ben-Dov; Joseph Tam
Journal:  Mol Metab       Date:  2020-09-26       Impact factor: 7.422

9.  Fatty Acid Metabolism and Derived-Mediators Distinctive of PPAR-α Activation in Obese Subjects Post Bariatric Surgery.

Authors:  Claudia Manca; Stefano Pintus; Elisabetta Murru; Giovanni Fantola; Michela Vincis; Barbara Batetta; Enrico Moroni; Gianfranca Carta; Sebastiano Banni
Journal:  Nutrients       Date:  2021-12-01       Impact factor: 5.717

Review 10.  Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.

Authors:  Justin Matheson; Xin Ming Matthew Zhou; Zoe Bourgault; Bernard Le Foll
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.